PUBLISHER: Inkwood Research | PRODUCT CODE: 1091860
PUBLISHER: Inkwood Research | PRODUCT CODE: 1091860
The Asia-Pacific Alzheimer's disease therapeutics & diagnostics market is set to progress with a 6.89% CAGR across the forecasting period of 2022 to 2030. The rising prevalence of dementia and rapidly growing population in developing countries are driving the market growth.
The Asia-Pacific Alzheimer's disease therapeutics & diagnostics market growth estimation covers the analysis of South Korea, Thailand, Indonesia, China, India, Vietnam, Australia & New Zealand, Japan, and Rest of Asia-Pacific. The Indian healthcare system is experiencing immense progress due to the growing economy. The demand for new healthcare technological advancements in the treatment and early diagnosis of dementia and cognitive impairment is rising due to the increasing burden of Alzheimer's disease throughout the country.
Furthermore, the entire population of South Korea is rapidly aging. According to the World Population Ageing 2019 report, the population aged above 65 years or above is expected to reach 12.658 million by 2030, which was 7.715 million in 2019. The surging geriatric population is prone to neurological disorders like Alzheimer's disease and other dementias, which is expected to drive the market over the forecast period.
Additionally, according to Alzheimer's Disease International, in 2015, Alzheimer's Indonesia launched a project called Dementia Friendly Jakarta with the governor's support. In 2012, there were nearly 21 million older people, and the projected number of patients suffering from Alzheimer's is expected to reach about 5,18,000 by 2024, supplementing the growth of the Indonesia Alzheimer's disease therapeutics & diagnostics market.
Prominent companies operating in the market include: Sun Pharmaceuticals Industries Ltd, GE Healthcare, Lupin Limited, Novartis AG, etc.